Journal
NEURAL REGENERATION RESEARCH
Volume 14, Issue 12, Pages 2035-2042Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/1673-5374.262571
Keywords
amyloid-beta peptide; A beta; neural stem cells; neural progenitor cells; Alzheimer's disease; amyloid precursor protein; toxicity; neurogenesis; gliogenesis; GSK3 beta
Categories
Funding
- MI-CINN-ISCIII [PI-10/00291, MPY1412/09]
- MINECO [SAF2015-71140-R]
- Comunidad de Madrid (NEUROSTEMCM consortium) [S2010/BMD-2336]
Ask authors/readers for more resources
Although amyloid-beta peptide is considered neurotoxic, it may mediate several physiological processes during embryonic development and in the adult brain. The pathological function of amyloid-beta peptide has been extensively studied due to its implication in Alzheimer's disease, but its physiological function remains poorly understood. Amyloid-beta peptide can be detected in non-aggregated (monomeric) and aggregated (oligomeric and fibrillary) forms. Each form has different cytotoxic and/or physiological properties, so amyloid-beta peptide and its role in Alzheimer's disease need to be studied further. Neural stem cells and neural precursor cells are good tools for the study on neurodegenerative diseases and can provide future therapeutic applications in diseases such as Alzheimer's disease. In this review, we provide an outline of the effects of amyloid-beta peptide, in monomeric and aggregated forms, on the biology of neural stem cells/neural precursor cells, and discuss the controversies. We also describe the possible molecular targets that could be implicated in these effects, especially GSK3 beta. A better understanding of amyloid-beta peptide (both physiological and pathological), and the signaling pathways involved are essential to advance the field of Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available